What is NanoDx?
NanoDx is a pioneering healthcare technology firm dedicated to the advancement of diagnostic precision through its proprietary nano biosensor platform. By integrating nanotechnology with sophisticated biological sensing, the company aims to deliver rapid, accurate, and accessible diagnostic data that empowers clinicians and patients alike. The firm's core mission centers on the development of scalable solutions that address critical gaps in current healthcare delivery, ultimately striving to improve patient outcomes and operational efficiencies across global health systems. As a leader in the biosensor space, NanoDx leverages its unique technological architecture to provide actionable insights, effectively bridging the gap between complex laboratory diagnostics and real-time clinical decision-making.
How much funding has NanoDx raised?
NanoDx has raised a total of $30.5M across 7 funding rounds:
Series A
$4M
Private Equity
$1.6M
Series B
$4M
Private Equity
$2M
Private Equity
$557K
Debt
$350K
Series C
$18M
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Series B (2016): $4M supported by Provident Healthcare Capital
Private Equity (2017): $2M featuring Provident Healthcare Capital and MedScience Ventures, LLC
Private Equity (2017): $557K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Series C (2020): $18M led by Shepherd Kaplan Krochuk, LLC
Key Investors in NanoDx
Provident Healthcare Capital
Provident Healthcare Partners specializes in healthcare investment banking, offering services such as mergers and acquisitions, equity and debt financing, and strategic advisory. The firm is dedicated to providing tailored transaction advisory services to privately-held healthcare companies across the United States.
MedScience Ventures, LLC
MedScience Ventures, LLC focuses on bridging life sciences and culture through strategic investments and collaborations. The company maintains a diverse investment portfolio aimed at fostering innovation in the life sciences sector.
Shepherd Kaplan Krochuk, LLC
An investment management firm providing strategic capital and financial oversight to support the growth and operational scaling of high-potential enterprises.
What's next for NanoDx?
With the recent influx of capital, NanoDx is well-positioned to transition into a phase of aggressive market expansion and product diversification. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the growing demand for its biosensor technology while simultaneously pursuing regulatory milestones in key international markets. Furthermore, the company is expected to leverage its current financial standing to forge deeper partnerships with healthcare providers and diagnostic networks, thereby cementing its role as an essential component of the modern medical infrastructure. As the firm continues to refine its platform, the emphasis will remain on enhancing the sensitivity and versatility of its sensors to address a broader spectrum of clinical conditions, ensuring long-term value creation for stakeholders and improved health outcomes for the global population.
See full NanoDx company page
